Sun Pharma's Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis
Shots:
- TGA approval is based on P-III reSURFACE data (N=1862) i.e. (reSURFACE 1 and reSURFACE 2) assessing Ilumya 100mg vs PBO or etanercept- showing PASI 75 reduction in psoriasis severity and Physician’s Global Assessment (PGA) score clear or minimal @12wks. after two doses
- Ilumya (tildrakizumab) 100mg is a SC injection administered q12w post 0 and 4 weeks’ initial dosage completion. A patient support program will be launched offering Illumya’s self-injection training by doctors- registered nurses- dose reminders- injection consumables and a patient support help line
- Ilumya is approved by the US FDA and EU for the treatment of moderate-to-severe plaque psoriasis candidates for systemic therapy in Mar and Sep 2018 respectively
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
